Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Seth David Rosen"'
Autor:
Ulka N. Vaishampayan, Piotr Tomczak, Jameel Muzaffar, Ira Seth Winer, Seth David Rosen, Christopher J. Hoimes, Aman Chauhan, Anna Spreafico, Karl D. Lewis, Debora S. Bruno, Olivier Dumas, David F. McDermott, James Fredric Strauss, Quincy S. Chu, Lucy Gilbert, Arvind Chaudhry, Julie R. Graham, Valentina Boni, Marc S. Ernstoff, Vamsidhar Velcheti
Publikováno v:
Journal of Clinical Oncology. 40:2500-2500
2500 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 (IL-2) receptor (IL-2R) to preferentially activate antitumor CD8+ T cells and natural killer
Autor:
Christopher J. Hoimes, Ulka N. Vaishampayan, Olivier Dumas, Valentina Boni, Marc S. Ernstoff, Yangchun Du, Anna Spreafico, Aman Chauhan, Arvind Chaudhry, Vamsidhar Velcheti, Ira Winer, Lucy Gilbert, Heather C. Losey, Ilda Bidollari, Jessicca Martin Rege, Jameel Muzaffar, Bruce Dezube, Quincy Chu, Piotr Tomczak, Seth David Rosen, Kelly Curtis, David F. McDermott, Elizabeth Dorn, Lei Sun, Yan Wang, James Strauss, Debora S. Bruno, Emily Putiri
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background ALKS 4230 is a novel engineered cytokine that selectively targets the intermediate-affinity interleukin-2 receptor complex to activate CD8+ T cells and natural killer cells.1 The ARTISTRY-1 trial (NCT02799095) has shown encouraging efficac
Autor:
Ulka N. Vaishampayan, Shipra Gandhi, Seth David Rosen, Anna Spreafico, Debora S. Bruno, Quincy S. Chu, Aman Chauhan, Olivier Dumas, Hal W. Hirte, Jared E. Lopes, Heather Losey, Yan Wang, Lei Sun, Monali Bhardwaj Desai, Rita P. Dalal, Yangchun Du, Julie R. Graham, Jameel Muzaffar, Ira Seth Winer
Publikováno v:
Journal of Clinical Oncology. 40:659-659
659 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel engineered cytokine that selectively binds to the intermediate-affinity IL-2 receptor, preferentially activating and expanding antitumor CD8+ T and NK cells, with minimal expansion
Autor:
Jessicca Martin Rege, Lucy Gilbert, Debora S. Bruno, Vamsidhar Velcheti, Ilda Bidollari, Arvind Chaudhry, Ulka N. Vaishampayan, Olivier Dumas, Yangchun Du, Valentina Boni, David F. McDermott, James Strauss, Piotr Tomczak, Quincy Chu, Marc S. Ernstoff, Anna Spreafico, Jameel Muzaffar, Ira Winer, Seth David Rosen, Aman Chauhan
Publikováno v:
Journal of Clinical Oncology. 39:2513-2513
2513 Background: Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds the intermediate-affinity interleukin-2 (IL-2) receptor complex to preferentially activate CD8+ T cells and natural killer cells with mi